[特拉匹韦：慢性丙型肝炎患者抗病毒治疗的新可能性]

[Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].

作者信息

Nikitin I G, Gogova L M, Baikova I E, Kislyakov V A, Volynkina V M

出版信息

Ter Arkh. 2012;84(11):75-80.

Abstract

The review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral agent, used to treat patients with chronic hepatitis C (CHC). The given data on Phase II and III clinical trials enable the authors to state the high efficacy of the drug in patients infected with hepatitis C virus type 1. The paper also provides data on the resistance of telaprevir and its drug interaction and denotes the place of the drug in the current antiviral treatment of patients with CHC.

摘要

这篇综述探讨了特拉匹韦（一种用于治疗慢性丙型肝炎患者的新型直接抗病毒药物）的化学结构、药效学和药代动力学。关于II期和III期临床试验的给定数据使作者能够指出该药物对1型丙型肝炎病毒感染患者具有高效性。本文还提供了特拉匹韦的耐药性及其药物相互作用的数据，并指明了该药物在当前慢性丙型肝炎患者抗病毒治疗中的地位。